Daclatasvir

Antiviral, Systemic · NS5A inhibitor

Indications

With other antivirals for the treatment of chronic Hepatitis C.

Dosage

Adults: 60 mg once daily, continue for up to 24 weeks. Children: Not recommended.

Adverse Effects

Fatigue, headache, anorexia, insomnia, pruritus, dry skin, alopecia, anaemia, GI upset, dry mouth, rash, myalgia, irritability, dizziness, migraine, hot flush, dyspnoea, nasal congestion, cough, arthralgia.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Child-Pugh C liver disease. Organ transplant recipients. Decompensated cirrhosis. Co-infection with HBV. Ensure contraception in women and continue for 5 weeks after treatment.

Interactions

NNRTIs, dabigartan, digoxin, oral contraceptives, statins, amiodarone. Strong or moderate CYP3A4 or P-gp inducers (e.g. phenytoin, carbamazepine, phenobarbital, rifampicin, systemic dexamethasone, St. John's Wort) or strong CYP3A4 inhibitors (e.g. boceprevir, telaprevir, atazanavir, cobicistat, macrolides, azole antifungals, calcium channel blockers).

Pharmacokinetics

Metabolism: Hepatic. Bioavailability: 67%. Half-life elimination: Approx. 12-15 hrs. Time to peak, plasma: =2 hrs. Excretion: Faeces (88%). Urine (6.6%).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.